World Lung Cancer Day (WLCD) is observed on August 1 every year. The one-day campaign provides an opportunity for the public health community to generate awareness about lung cancer issues and draw attention to the need for more lung cancer research funding. Lung cancer is one of the most common cancers worldwide, claiming more lives yearly than breast, colon and prostate cancers combined. According to the World Health Organization (WHO), lung cancer accounts for around 1 in 5 deaths caused due to cancer globally. Lung cancer mortality is projected to reach 2.45 million by 2030, a 39 percent increase in just over a decade. The condition is more common among older people, with the average age of diagnosis being 70 years. People who are habitual smokers are at high risk of developing lung cancer in the long run. Treatment modalities may depend on the type, severity and stage of the cancer. Billing and coding for this type of cancer can be challenging. Oncologists or other specialists who treat lung cancer patients need to correctly understand the usage of medical codes. Relying on the services of reputable medical billing and coding companies with ample expertise in this field can ensure billing and coding efficiency.
The International Association for the Study of Lung Cancer (IASLC) hosts the World Conference on Lung Cancer (WCLC), which is the world’s largest conference dedicated to lung cancer. The 2022 observance aims to spread awareness about lung cancer and its global impact, creating an educational movement of understanding lung cancer risks as well as early treatment around the world. It urges everyone to learn about risk factors for the disease and highlight the importance of early detection through lung cancer screening. As mentioned above, smoking and second-hand exposure to smoke is the main factor that causes this type of cancer. However, it also occurs in people who never smoked and who never had prolonged exposure to secondhand smoke. In these cases, there may be no clear cause of the cancer.
Typically, lung cancer does not display any specific signs and symptoms in its earliest stages. However, when the condition reaches an advanced stage, certain symptoms occur. Common symptoms include – a new cough (that doesn’t go away), headache, shortness of breath, chest pain, bone pain and coughing up blood (even a small amount). The observance aims to reduce the social stigma about the condition among the lung cancer community and emphasizes the key risk factors as well as screening and treatment options. Diagnosis of this condition may involve performing several imaging tests like – Computed Tomography (CT) scan, Chest X-rays, Bronchoscopy, Sputum cytology and Fine-needle aspiration (FNA) biopsy of the lung. These tests help identify the condition in its early stages before it spreads to the lymph nodes or other areas of the body. Upon diagnosis of the condition, oncologists would determine the right treatment option.
Medicare Part B provides coverage for lung cancer screening with Low Dose Computed Tomography (LDCT) once a year for all eligible patients. The LDCT annual coverage is offered to people in the age group of 55-77 years. People in this age group must be either current smokers or have quit smoking in the previous 15 years, who are asymptomatic, who have a 30-pack-year history of tobacco smoking (an average of one pack a day for 30 years), and who have a written order from a physician or qualified non-physician practitioner that meets certain requirements. The coverage includes a visit for counseling and shared decision-making on the benefits and risks of cancer screening. Correct billing and coding is essential on the part of oncologists or medical coding outsourcing companies to ensure proper reimbursement.
ICD-10 Diagnosis Codes For Lung Cancer
- C34 Malignant neoplasm of bronchus and lung
- C34.0 Malignant neoplasm of main bronchus
- C34.1 Malignant neoplasm of upper lobe, bronchus or lung
- C34.2 Malignant neoplasm of middle lobe, bronchus or lung
- C34.3 Malignant neoplasm of lower lobe, bronchus or lung
- C34.8 Malignant neoplasm of overlapping sites of bronchus and lung
- C34.9 Malignant neoplasm of unspecified part of bronchus or lung
The campaign was first organized in the year 2012 by the Forum of International Respiratory Societies, in collaboration with the International Association for the Study of Lung Cancer (IASLC) and also the American College of Chest Physicians (CHEST). The IASLC World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies.
Apart from striving to prevent occurrences of lung cancer in the global population, WLCD also honors and commemorates every single person impacted by lung cancer. A wide range of activities are organized as part of the campaign and these include – distributing fact sheets about the campaign, attending lung cancer screening programs, sharing stories and posts by lung cancer survivors and lung cancer research, using hashtags like – #LivingWithLungCancer, #WLCD2022 via prominent social media platforms.